Alan R Smyth

List of Publications by Year
in descending order

190 papers	8,821 citations	61857 43 h-index	49773 87 g-index
206 all docs	206 docs citations	206 times ranked	9117 citing authors

#	Article	IF	Citations
1	Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. European Respiratory Journal, 2000, 16, 749.	3.1	556
2	ECFS best practice guidelines: the 2018 revision. Journal of Cystic Fibrosis, 2018, 17, 153-178.	0.3	521
3	Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals. Annals of the American Thoracic Society, 2019, 16, 22-28.	1.5	458
4	European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. Journal of Cystic Fibrosis, 2014, 13, S23-S42.	0.3	438
5	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax, 2016, 71, i1-i22.	2.7	348
6	Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet, The, 1994, 343, 85-86.	6.3	309
7	Oral Prednisolone for Preschool Children with Acute Virus-Induced Wheezing. New England Journal of Medicine, 2009, 360, 329-338.	13.9	296
8	US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax, 2016, 71, 88-90.	2.7	274
9	Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study. BMJ: British Medical Journal, 2012, 344, d7373-d7373.	2.4	235
10	European best practice guidelines for cystic fibrosis neonatal screening. Journal of Cystic Fibrosis, 2009, 8, 153-173.	0.3	196
11	Development and Reporting of Prediction Models: Guidance for Authors From Editors of Respiratory, Sleep, and Critical Care Journals. Critical Care Medicine, 2020, 48, 623-633.	0.4	188
12	The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers. Thorax, 2018, 73, 388-390.	2.7	181
13	Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosisâ€"the TOPIC study: a randomised controlled trial. Lancet, The, 2005, 365, 573-578.	6.3	176
14	Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.. Archives of Disease in Childhood, 1995, 73, 117-120.	1.0	163
15	Asthma as a Barrier to Children's Physical Activity: Implications for Body Mass Index and Mental Health. Pediatrics, 2006, 118, 2443-2449.	1.0	152
16	A Glycopeptide Dendrimer Inhibitor of the Galactoseâ€Specific Lectin LecA and of Pseudomonas aeruginosa Biofilms. Angewandte Chemie - International Edition, 2011, 50, 10631-10635.	7.2	149
17	Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. , 2014, , CD004197.		120
18	Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis. Thorax, 2010, 65, 654-658.	2.7	119

#	Article	IF	Citations
19	Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosisâ€"a pilot randomized controlled trial. Pediatric Pulmonology, 2010, 45, 356-362.	1.0	116
20	Results of antibiotic susceptibility testing do not influence clinical outcome in children with cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 288-292.	0.3	113
21	Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax, 2008, 63, 532-535.	2.7	100
22	Novel approaches to the treatment ofPseudomonas aeruginosainfections in cystic fibrosis. European Respiratory Journal, 2012, 40, 1014-1023.	3.1	100
23	Pseudomonas aeruginosaquorum sensing molecules correlate with clinical status in cystic fibrosis. European Respiratory Journal, 2015, 46, 1046-1054.	3.1	95
24	Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity. Current Opinion in Pulmonary Medicine, 2010, 16, 604-610.	1.2	94
25	Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19. Thorax, 2021, 76, 907-919.	2.7	90
26	A Randomized, Controlled Trial of an Interactive Educational Computer Package for Children With Asthma. Pediatrics, 2006, 117, 1046-1054.	1.0	88
27	Comparison of oral amoxicillin and intravenous benzyl penicillin for community acquired pneumonia in children (PIVOT trial): a multicentre pragmatic randomised controlled equivalence trial. Thorax, 2007, 62, 1102-1106.	2.7	87
28	Cystic fibrosis microbiology: Advances in antimicrobial therapy. Journal of Cystic Fibrosis, 2015, 14, 551-560.	0.3	83
29	Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ: British Medical Journal, 2011, 343, d4662-d4662.	2.4	79
30	Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. The Cochrane Library, 2020, 2020, CD004197.	1.5	79
31	Survey of acute renal failure in patients with cystic fibrosis in the UK. Thorax, 2007, 62, 541-545.	2.7	78
32	Risk Factors for Chronic Kidney Disease in Adults with Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1147-1152.	2.5	72
33	Exacerbations in cystic fibrosis: 3 {middle dot} Management. Thorax, 2007, 63, 180-184.	2.7	68
34	Rate of improvement of CF life expectancy exceeds that of general populationâ€"Observational death registration study. Journal of Cystic Fibrosis, 2014, 13, 410-415.	0.3	66
35	Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. , 2009, , CD004197.		63
36	A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2015, 14, 507-514.	0.3	62

#	Article	IF	Citations
37	Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections. Clinical Infectious Diseases, 2019, 69, 1812-1816.	2.9	62
38	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. , 2003, , CD001912.		61
39	Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 819-823.	2.5	61
40	Population pharmacokinetics of tobramycin administered thrice daily and once daily in children and adults with cystic fibrosis. Journal of Cystic Fibrosis, 2007, 6, 327-333.	0.3	61
41	Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials. Journal of Cystic Fibrosis, 2020, 19, 499-502.	0.3	60
42	A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients. Journal of Cystic Fibrosis, 2016, 15, 495-502.	0.3	59
43	Rationalised prescribing for community acquired pneumonia: a closed loop audit. Archives of Disease in Childhood, 2000, 83, 320-324.	1.0	58
44	Parenchymal lung abnormalities following hospitalisation for COVID-19 and viral pneumonitis: a systematic review and meta-analysis. Thorax, 2023, 78, 191-201.	2.7	49
45	Core Outcomes Set for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1622-1635.	0.4	47
46	Asthma as a Barrier to Children's Physical Activity: In Reply. Pediatrics, 2007, 119, 1248-1249.	1.0	45
47	Addressing resistance to antibiotics in systematic reviews of antibiotic interventions. Journal of Antimicrobial Chemotherapy, 2016, 71, 2367-2369.	1.3	45
48	Receiver operating characteristic curves for comparison of serial neutrophil band forms and C reactive protein in neonates at risk of infection.. Archives of Disease in Childhood, 1992, 67, 808-812.	1.0	44
49	Clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 2007, 6, 85-99.	0.3	41
50	Pneumonia in the developed world. Paediatric Respiratory Reviews, 2011, 12, 60-69.	1.2	41
51	Core Outcome Measures for Trials in People With Coronavirus Disease 2019: Respiratory Failure, Multiorgan Failure, Shortness of Breath, and Recovery. Critical Care Medicine, 2021, 49, 503-516.	0.4	41
52	Exhaled breath hydrogen cyanide as a marker of earlyPseudomonas aeruginosainfection in children with cystic fibrosis. ERJ Open Research, 2015, 1, 00044-2015.	1.1	40
53	Respiratory medicines for children: current evidence, unlicensed use and research priorities. European Respiratory Journal, 2010, 35, 247-265.	3.1	39
54	Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respiratory Medicine,the, 2020, 8, 975-986.	5.2	38

#	Article	IF	Citations
55	Update on treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2006, 12, 440-444.	1.2	36
56	Absence of Cochleotoxicity Measured by Standard and High-Frequency Pure Tone Audiometry in a Trial of Once- versus Three-Times-Daily Tobramycin in Cystic Fibrosis Patients. Antimicrobial Agents and Chemotherapy, 2006, 50, 2293-2299.	1.4	36
57	Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study. Journal of Cystic Fibrosis, 2017, 16, 230-238.	0.3	36
58	Prophylactic Antibiotics in Cystic Fibrosis: A Conviction without Evidence?. Pediatric Pulmonology, 2005, 40, 471-476.	1.0	35
59	Are Measures of Body Habitus Associated With Mortality in Cystic Fibrosis?. Chest, 2012, 142, 712-717.	0.4	35
60	Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. The Cochrane Library, 2015, , CD009650.	1.5	35
61	Using digital technology for home monitoring, adherence and self-management in cystic fibrosis: a state-of-the-art review. Thorax, 2020, 75, 72-77.	2.7	35
62	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane Library, 2017, 3, CD002009.	1.5	34
63	Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. , 2006, , CD004197.		33
64	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2017, 4, CD001912.	1.5	33
65	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2006, , CD002009.		29
66	Postprandial changes in gastrointestinal function and transit in cystic fibrosis assessed by Magnetic Resonance Imaging. Journal of Cystic Fibrosis, 2021, 20, 591-597.	0.3	29
67	The Management of Pre-School Wheeze. Paediatric Respiratory Reviews, 2011, 12, 70-77.	1.2	27
68	Therapeutic approaches to chronic cystic fibrosis respiratory infections with available, emerging aerosolized antibiotics. Respiratory Medicine, 2011, 105, S2-S8.	1.3	26
69	Oral versus i.v. antibiotics for community-acquired pneumonia in children: a cost-minimisation analysis. European Respiratory Journal, 2010, 35, 858-864.	3.1	25
70	Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. Annals of the American Thoracic Society, 2018, 15, 42-48.	1.5	24
71	Adapting the James Lind Alliance priority setting process to better support patient participation: an example from cystic fibrosis. Research Involvement and Engagement, 2019, 5, 24.	1.1	24
72	Time to get serious about the detection and monitoring of early lung disease in cystic fibrosis. Thorax, 2021, 76, 1255-1265.	2.7	24

#	Article	IF	Citations
73	Effective treatment strategies for paediatric community-acquired pneumonia. Expert Opinion on Pharmacotherapy, 2007, 8, 1091-1101.	0.9	22
74	How can we relieve gastrointestinal symptoms in people with cystic fibrosis? An international qualitative survey. BMJ Open Respiratory Research, 2020, 7, e000614.	1.2	22
75	Lack of concordance in the use and monitoring of intravenous aminoglycosides in UK cystic fibrosis centers. Pediatric Pulmonology, 2002, 33, 165-165.	1.0	21
76	Aerosolized antibiotic therapy for chronic cystic fibrosis airway infections: continuous or intermittent?. Respiratory Medicine, 2011, 105, S9-S17.	1.3	21
77	Double click for health: the role of multimedia in asthma education. Archives of Disease in Childhood, 2001, 85, 447-449.	1.0	20
78	Pneumonia due to viral and atypical organisms and their sequelae. British Medical Bulletin, 2002, 61, 247-262.	2.7	20
79	The Asthma Files: Evaluation of a multimedia package for childrenâ€™s asthma education. Paediatric Nursing, 2002, 14, 32-35.	0.1	19
80	Educational interventions â€“ computers for delivering education to children with respiratory illness and to their parents. Paediatric Respiratory Reviews, 2005, 6, 215-226.	1.2	19
81	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2012, , CD002009.		19
82	Perception of first respiratory infection with Pseudomonas aeruginosa by people with cystic fibrosis and those close to them: an online qualitative study. BMJ Open, 2016, 6, e012303.	0.8	19
83	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. , 2012, 12, CD001912.		18
84	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. The Cochrane Library, 2013, , CD008037.	1.5	18
85	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2010, , CD002009.		17
86	Treatment massive haemoptysis in cystic fibrosis with tranexamic acid. Journal of the Royal Society of Medicine, 2011, 104, 49-52.	1.1	17
87	Standards of Care for Cystic Fibrosis ten years later. Journal of Cystic Fibrosis, 2014, 13, S1-S2.	0.3	17
88	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. The Cochrane Library, 2016, , CD009530.	1.5	17
89	Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. The Cochrane Library, 2018, 7, CD009650.	1.5	17
90	Can exercise replace airway clearance techniques in cystic fibrosis? A survey of patients and healthcare professionals. Journal of Cystic Fibrosis, 2020, 19, e19-e24.	0.3	17

#	Article	IF	Citations
91	What effective ways of motivation, support and technologies help people with cystic fibrosis improve and sustain adherence to treatment?. BMJ Open Respiratory Research, 2020, 7, e000601.	1.2	17
92	Preprint servers: a â€˜rush to publishâ€™ or â€˜just in time deliveryâ€™ for science?. Thorax, 2020, 75, 532-533.	2.7	17
93	Is microfinance associated with changes in womenâ€™s well-being and childrenâ€™s nutrition? A systematic review and meta-analysis. BMJ Open, 2019, 9, e023658.	0.8	16
94	Intestinal function and transit associate with gut microbiota dysbiosis in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 506-513.	0.3	16
95	Bronchial asthma on Mount Kilimanjaro is not a disadvantage. Thorax, 2008, 63, 936-937.	2.7	14
96	Treatment strategies for cystic fibrosis: what's in the pipeline?. Expert Opinion on Pharmacotherapy, 2009, 10, 1191-1202.	0.9	14
97	Current dilemmas in antimicrobial therapy in cystic fibrosis. Expert Review of Respiratory Medicine, 2012, 6, 407-422.	1.0	14
98	Risk-proportionate clinical trial monitoring: an example approach from a non-commercial trials unit. Trials, 2014, 15, 127.	0.7	14
99	Staphylococcus aureus in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2018, 24, 586-591.	1.2	14
100	Infection prevention and control in cystic fibrosis: a systematic review of interventions. Expert Review of Respiratory Medicine, 2019, 13, 425-434.	1.0	14
101	Parental attitudes: antenatal diagnosis of cystic fibrosis. Archives of Disease in Childhood, 2002, 87, 284-286.	1.0	13
102	Evaluating the effectiveness of a schools-based programme to promote exercise self-efficacy in children and young people with risk factors for obesity: Steps to active kids (STAK). BMC Public Health, 2011, 11, 830.	1.2	13
103	Bronchoscopy-guided antimicrobial therapy for cystic fibrosis. , 2013, , CD009530.		13
104	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. , 2014, , CD001912.		13
105	Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review. Journal of Cystic Fibrosis, 2020, 19, 858-867.	0.3	13
106	Rojiroti microfinance and child nutrition: a cluster randomised trial. Archives of Disease in Childhood, 2020, 105, 229-235.	1.0	13
107	Antimicrobial resistance: Concerns of healthcare providers and people with CF. Journal of Cystic Fibrosis, 2021, 20, 407-412.	0.3	13
108	Prescribing practices for intravenous aminoglycosides in UK Cystic Fibrosis clinics: A questionnaire survey. Journal of Cystic Fibrosis, 2014, 13, 424-427.	0.3	12

#	Article	IF	Citations
109	Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review. Thorax, 2019, 74, 229-236.	2.7	12
110	International Survey to Establish Prioritized Outcomes for Trials in People With Coronavirus Disease 2019. Critical Care Medicine, 2020, 48, 1612-1621.	0.4	12
111	An ex vivo cystic fibrosis model recapitulates key clinical aspects of chronic Staphylococcus aureus infection. Microbiology (United Kingdom), 2021, 167, .	0.7	12
112	The measurement properties of tests and tools used in cystic fibrosis studies: a systematic review. European Respiratory Review, 2021, 30, 200354.	3.0	12
113	Antibiotics and Acute Renal Failure in Children with Cystic Fibrosis. Paediatric and Perinatal Drug Therapy, 2002, 5, 65-67.	0.6	12
114	Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls. Journal of Cystic Fibrosis, 2022, 21, 502-505.	0.3	12
115	Treatment of pulmonary exacerbations in cystic fibrosis. Current Opinion in Pulmonary Medicine, 2020, 26, 679-684.	1.2	11
116	Trends in passive smoking in cystic fibrosis, 1993-1998. Pediatric Pulmonology, 2001, 31, 133-137.	1.0	10
117	Acute rib fracture pain in CF. Thorax, 2001, 56, 819-819.	2.7	10
118	Interventions for the eradication of methicillin-resistantStaphylococcus aureus(MRSA) in people with cystic fibrosis. , 2013, , CD009650.		10
119	Transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet, The, 1993, 342, 434-435.	6.3	9
120	Do current clinical trials in cystic fibrosis match the priorities of patients and clinicans? A systematic review. Journal of Cystic Fibrosis, 2020, 19, 26-33.	0.3	9
121	Porphyromonas pasteri and Prevotella nanceiensis in the sputum microbiota are associated with increased decline in lung function in individuals with cystic fibrosis. Journal of Medical Microbiology, 2022, 71, .	0.7	9
122	Tobramycin dosing in cystic fibrosis. Lancet, The, 2005, 365, 1767-1768.	6.3	8
123	Multiresistant pulmonary infection in cystic fibrosisâ€"prevention is better than cure. Lancet, The, 2005, 366, 433-435.	6.3	8
124	Delayed publication of clinical trials in cystic fibrosis. Journal of Cystic Fibrosis, 2012, 11, 14-17.	0.3	8
125	Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study. Journal of Cystic Fibrosis, 2013, 12, 284-289.	0.3	8
126	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. , 2014, , CD002009.		8

#	Article	IF	Citations
127	Treatments for preventing recurrence of infection with Pseudomonas aeruginosa in people with cystic fibrosis. The Cochrane Library, 2019, 12, CD012300.	1.5	8
128	Minimizing the toxicity of aminoglycosides in cystic fibrosis. Journal of the Royal Society of Medicine, 2010, 103, 3-5.	1.1	7
129	Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis. Therapeutic Advances in Respiratory Disease, 2012, 6, 363-373.	1.0	7
130	Telehealth after the pandemic: Will the inverse care law apply? (Commentary). Journal of Cystic Fibrosis, 2021, 20, 47-48.	0.3	7
131	Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. The Cochrane Library, 2020, 2020, CD001912.	1.5	7
132	Impact of a case management protocol for childhood pneumonia in a rural Zambian hospital. Annals of Tropical Paediatrics, 1998, 18, 155-160.	1.0	6
133	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. , 2010, , CD008037.		6
134	Treatment of pulmonary exacerbations in cystic fibrosis â€“ could do better?. Paediatric Respiratory Reviews, 2016, 20, 6-7.	1.2	6
135	Novel detection of specific bacterial quorum sensing molecules in saliva: Potential non-invasive biomarkers for pulmonary Pseudomonas aeruginosa in cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 626-629.	0.3	6
136	Clinical significance of Pseudomonas aeruginosa 2-alkyl-4-quinolone quorum-sensing signal molecules for long-term outcomes in adults with cystic fibrosis. Journal of Medical Microbiology, 2019, 68, 1823-1828.	0.7	6
137	Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Health Technology Assessment, 2021, 25, 1-128.	1.3	6
138	Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial. Pediatric Pulmonology, 2016, 51, 253-257.	1.0	5
139	Climate change and lung health: the challenge for a new president. Thorax, 2017, 72, 295-296.	2.7	5
140	Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. The Cochrane Library, 2019, 2019, CD002009.	1.5	5
141	2-Alkyl-4-quinolone quorum sensing molecules are biomarkers for culture-independent Pseudomonas aeruginosa burden in adults with cystic fibrosis. Journal of Medical Microbiology, 2021, 70, .	0.7	5
142	Pseudomonas eradication in cystic fibrosis: who will join the ELITE?. Thorax, 2010, 65, 281-282.	2.7	4
143	Embracing social media: TableÂ1. Thorax, 2015, 70, 1112-1112.	2.7	4
144	The patient voice in research â€” Supporting actor or starring role?. Journal of Cystic Fibrosis, 2017, 16, 313-314.	0.3	4

#	Article	IF	Citations
145	Infection prevention and control in cystic fibrosis: One size fits all The argument against. Paediatric Respiratory Reviews, 2020, 36, 94-96.	1.2	4
146	A randomised controlled trial of rosuvastatin for the prevention of aminoglycoside-induced kidney toxicity in children with cystic fibrosis. Scientific Reports, 2020, 10, 1796.	1.6	4
147	Timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. The Cochrane Library, 2021, 2021, CD013488.	1.5	4
148	Novel method to select meaningful outcomes for evaluation in clinical trials. BMJ Open Respiratory Research, 2021, 8, e000877.	1.2	4
149	Preferred health outcome states following treatment for pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 581-587.	0.3	4
150	Birth Cohorts in Childhood Asthma: Lessons and Limitations. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 238-239.	2.5	3
151	From pipeline to patient: new developments in cystic fibrosis therapeutics. Expert Opinion on Pharmacotherapy, 2013, 14, 323-329.	0.9	3
152	Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review. Thorax, 2018, 73, 670-673.	2.7	3
153	Industry influence in healthcare harms patients: myth or maxim?. Breathe, 2022, 18, 220010.	0.6	3
154	A study of a single high potency multivitamin preparation in the management of cystic fibrosis. Journal of Human Nutrition and Dietetics, 1998, 11, 493-500.	1.3	2
155	Once-daily tobramycin monotherapy in cystic fibrosis. Pediatric Pulmonology, 2002, 33, 406-406.	1.0	2
156	Feasibility and pilot study of the effects of microfinance on mortality and nutrition in children under five amongst the very poor in India: study protocol for a cluster randomized controlled trial. Trials, 2014, 15, 298.	0.7	2
157	Patient engagement to prioritise CF research: Inclusive or selective?. Journal of Cystic Fibrosis, 2019, 18, 307-308.	0.3	2
158	The prevalence, clinical status and genotype of cystic fibrosis patients living in Cuba using national registry data. Journal of Cystic Fibrosis, 2019, 18, 522-524.	0.3	2
159	Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. The Cochrane Library, 2020, 2020, CD008037.	1.5	2
160	Digital technology for monitoring adherence to inhaled therapies in people with cystic fibrosis. The Cochrane Library, 0, , .	1.5	2
161	Smoking ban in cars protects children, but is vaping â€˜The Elephant in the Carâ€™?. Thorax, 2020, 75, 297-297.	2.7	2
162	Perspectives of patients, family members, health professionals and the public on the impact of COVID-19 on mental health. Journal of Mental Health, 2022, 31, 524-533.	1.0	2

#	Article	IF	Citations
163	Systematic review of antistaphylococcal antibiotic therapy in cystic fibrosis. Thorax, 2000, 55, 251-251.	2.7	1
164	Twice vs three times daily antibiotics in the treatment of pulmonary exacerbations of cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 383.	0.3	1
165	20 Years of Cochrane Glancing backwards â€“ Moving ahead: a tale of two Cochrane Review Groups. Paediatric Respiratory Reviews, 2013, 14, 165-167.	1.2	1
166	Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis. Paediatric Respiratory Reviews, 2013, 14, 27-28.	1.2	1
167	Finding and filling the gaps in the evidence with high quality clinical trials â€“ the experience of one Cochrane Review Group. Journal of Evidence-Based Medicine, 2013, 6, 229-231.	2.4	1
168	Editorial â€¢ Cochrane review: antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Journal of Evidence-Based Medicine, 2015, 8, 168-169.	2.4	1
169	Optimising respiratory health in children with cystic fibrosis. Paediatrics and Child Health (United) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	1
170	Treatments for preventing recurrence of infection withPseudomonas aeruginosain people with cystic fibrosis. The Cochrane Library, 0, , .	1.5	1
171	Weight gain during acute treatment of an initial pulmonary exacerbation is associated with a longer interval to the next exacerbation in adults with cystic fibrosis. ERJ Open Research, 2017, 3, 00057-2017.	1.1	1
172	Climate change and lung health: presidential failure, professional responsibility. Thorax, 2019, 74, 627-628.	2.7	1
173	Exploring the challenges of accessing medication for patients with cystic fibrosis. Thorax, 2022, 77, 295-297.	2.7	1
174	Optimizing respiratory health in children with cystic fibrosis. Paediatrics and Child Health (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	0
175	A clinical approach to a wheezy infant. Paediatrics and Child Health (United Kingdom), 2012, 22, 307-309.	0.2	0
176	New agents to treat lung infection in cystic fibrosis: a big enough leap?. Future Medicinal Chemistry, 2013, 5, 117-120.	1.1	0
177	Testing children of HIV-positive parents: a multidisciplinary approach. Archives of Disease in Childhood, 2014, 99, 789-790.	1.0	0
178	Evidence into practice: How do we get past the roadblocks?. Paediatric Respiratory Reviews, 2014, 15, 45-46.	1.2	0
179	The first thoracic triumvirate. Thorax, 2015, 70, 917-917.	2.7	0
180	Thoraxprotocol review: working with trialists to improve trial quality. Thorax, 2016, 71, 491-492.	2.7	0

#	Article	IF	Citations
181	First year of the thoracic triumvirate. Thorax, 2016, 71, 579-580.	2.7	0
182	Response to Journal Club: Cluster Randomized Trial Evaluating Impact of a Community-based Microfinance Scheme on Childhood Nutritional Status: Evidence-based Medicine Viewpoint. Indian Pediatrics, 2020, 57, 688-690.	0.2	0
183	A systematic Cochrane Review of antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Paediatric Respiratory Reviews, 2020, 36, 109-111.	1.2	0
184	Professor Pangloss and the Pangenome: Does Staphylococcus aureus Have the Best of All Possible Worlds?. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 1055-1057.	2.5	0
185	A systematic cochrane review of the timing of pancreatic enzyme replacement therapy (PERT) in cystic fibrosis. Paediatric Respiratory Reviews, 2021, 40, 44-45.	1.2	0
186	Cystic Fibrosis Therapies. , 2022, , 179-187.		0
187	Drug Development for Children. Paediatric and Perinatal Drug Therapy, 2002, 5, 2-3.	0.6	0
188	Daily Bread: Womenâ€™s Self-Help Microfinance and the Social Meanings of Money. Sociological Research Online, 2023, 28, 442-461.	0.7	0
189	Response to Journal Club: Cluster Randomized Trial Evaluating Impact of a Community-based Microfinance Scheme on Childhood Nutritional Status: Evidence-based Medicine Viewpoint. Indian Pediatrics, 2020, 57, 688-689.	0.2	0
190	Wheeze in the time of COVID-19: overcoming obstacles to an unusual diagnosis. Thorax, 2022, 77, 1050-1053.	2.7	0